Final overall survival (OS) for abemaciclib plus trastuzumab plus /- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+advanced breast cancer (monarcHER): A randomized, open-label, phase II trial

被引：16

作者：

Andre, F. ^{[1
]}

Nadal, J. C. ^{[2
]}

Denys, H. ^{[3
]}

Goel, S. ^{[4
]}

Litchfield, L. M. ^{[5
]}

Appiah, A. ^{[5
]}

Chen, Y. ^{[5
]}

Tolaney, S. M. ^{[6
]}

机构：

[1] Gustave Roussy Canc Campus, Dept Med Oncol, Breast Canc Unit, Villejuif, France

[2] Inst Alexander Fleming, Dept Clin Oncol, Buenos Aires, DF, Argentina

[3] Univ Ziekenhuis Gent, Dept Med Oncol, Ghent, Belgium

[4] Peter MacCallum Canc Ctr, Dept Canc Res, Melbourne, Vic, Australia

[5] Eli Lilly & Co Global Headquarters, Oncol, Indianapolis, IN USA

[6] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.08.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA18

引用

页码：S1386 / S1387

页数：2

共 50 条

[31] Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: A multicenter, randomized, open-label phase II study.
Peng, Zhi
Zhang, Xiaotian
Liang, Han
Zheng, Zhichao
Wang, Zhenning
Liu, Hao
Hu, Jiankun
Sun, Yihong
Zhang, Yanqiao
Yan, Han
Tong, Lin
Xu, Jiahui
Xie, Jessica
Ji, Jiafu
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 312 - 312
[32] MONARCHplus: A phase III trial of abemaciclib plus nonsteroidal aromatase inhibitor (NSAI) or fulvestrant (F) for women with HR+/HER2-advanced breast cancer (ABC)
Jiang, Z.
Hu, X.
Zhang, Q.
Sun, T.
Yin, Y.
Li, H.
Costa, R.
Yan, M.
Oppermann, C.
Tong, Z.
Liu, Y.
Zhang, Y.
Cheng, Y.
Ouyang, Q.
Chen, X.
Liao, N.
Wu, X.
Wang, X.
Han, R.
Lu, Y.
ANNALS OF ONCOLOGY, 2019, 30 : 863 - 863
[33] MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC)
Goetz, M. P.
Toi, M.
Huober, J.
Sohn, J.
Tredan, O.
Park, I. H.
Campone, M.
Chen, S. C.
Sanchez, L. M. Manso
Paluch-Shimon, S.
van Hal, G.
Shahir, A.
Iwata, H.
Johnston, S.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1384 - S1384
[34] Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
Harbeck, Nadia
Huang, Chiun-Sheng
Hurvitz, Sara
Yeh, Dah-Cherng
Shao, Zhimin
Im, Seock-Ah
Jung, Kyung Hae
Shen, Kunwei
Ro, Jungsil
Jassem, Jacek
Zhang, Qingyuan
Im, Young-Hyuck
Wojtukiewicz, Marek
Sun, Qiang
Chen, Shin-Cheh
Goeldner, Rainer-Georg
Uttenreuther-Fischer, Martina
Xu, Binghe
Piccart-Gebhart, Martine
LANCET ONCOLOGY, 2016, 17 (03): : 357 - 366
[35] SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+metastatic breast cancer
Rugo, H. S.
Pegram, M. D.
Gradishar, W. J.
Cortes, J.
Curigliano, G.
Hong, S.
Wigginton, J. M.
Lechleider, R. J.
Cardoso, F.
CANCER RESEARCH, 2017, 77
[36] Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer
Piccart, Martine
Procter, Marion
Fumagalli, Debora
de Azambuja, Evandro
Clark, Emma
Ewer, Michael S.
Restuccia, Eleonora
Jerusalem, Guy
Dent, Susan
Reaby, Linda
Bonnefoi, Herve
Krop, Ian
Liu, Tsang-Wu
Pienkowski, Tadeusz
Toi, Masakazu
Wilcken, Nicolas
Andersson, Michael
Im, Young-Hyuck
Tseng, Ling-Ming
Lueck, Hans-Joachim
Colleoni, Marco
Monturus, Estefania
Sicoe, Mihaela
Guillaume, Sebastien
Bines, Jose
Gelber, Richard
Viale, Giuseppe
Thomssen, Christoph
CANCER RESEARCH, 2020, 80 (04)
[37] HERmione: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with physician's choice of chemotherapy plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer, previously treated with pe
Miller, Kathy
Cortes, Javier
Hurvitz, Sara A.
Krop, Ian E.
Tripathy, Debu
Verma, Sunil
Riahi, Kaveh
Yardley, Denise A.
CANCER RESEARCH, 2015, 75
[38] An open-label randomized, multicenter, phase II study on neoadjuvant treatment with trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus bevacizumab according to positron emission tomography (PET) value modification in patients with early stage HER2-positive breast cancer (AVATAXHER): Design description
Cochet, Alexandre
Kerrou, Khaldoun
Nabholtz, Jean-Marc A.
Cachin, Florent
Pierga, Jean-Yves
Champion, Laurence
Ferrero, Jean-Marc
Darcourt, Jacques
Petit, Thierry
Bourahla, Khalil
Bougnoux, Philippe
Baulieu, Jean-Louis
Dupre, Pierre-Francois
Salaun, Pierre-Yves
Bachelot, Thomas Denis
Mognetti, Thomas
Coeffic, David Emmanuel
Mesnard, Nathalie
Coudert, Bruno P.
Berriolo-Riedinger, Alina
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[39] postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy
Kalinsky, Kevin
Layman, Rachel M.
Kaufman, Peter A.
Graff, Stephanie L.
Bianchini, Giampaolo
Martin, Miguel
Zhou, Yanhong
Knoderer, Holly
Litchfield, Lacey
Andrew Wander, Seth
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[40] MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2-advanced breast cancer
Goetz, Matthew
Toi, Masakazu
Huober, Jens
Sohn, Joo Hyuk
Tredan, Olivier
Park, Inhae
Campone, Mario
Chen, Shin-Cheh
Manso, Luis Manual
Paluch-Shimon, Shani
Freedman, Orit C.
Andre, Valerie
Saha, Abhijoy
van Hal, Gertjan
Shahir, Ashwin
Iwata, Hiroji
Johnston, Stephen R. D.
O'Shaughnessy, Joyce
Pivot, Xavier
Tolaney, Sara
Hurvitz, Sara
Llombart, Antonio
CANCER RESEARCH, 2024, 84 (09)

← 1 2 3 4 5 →